Pfizer Stops Enrollment In COVID-Pill Trial After Latest Lousy Results

Pfizer has announced it will stop enrollment in a clinical trial for Paxlovid – its COVID-19 antiviral pill – for standard-risk COVID-19 patients after the latest results suggested the drug did not reduce symptoms or hospitalizations and deaths to a statistically significant degree.

Paxlovid, which consists of two different antiviral drugs – nirmatrelvir and ritonavir – is currently approved or authorized for conditional or emergency use in more than 65 countries, including the United States, to treat COVID-19 patients at high risk of severe illness, including hospitalization or death.

Pfizer said on June 14 that it will “cease enrollment into the EPIC-SR trial due to low rate of hospitalization or death in the standard-risk population.”

However, the company said it will still include the new data in its upcoming application to the U.S. Food and Drug Administration (FDA) to seek full approval for Paxlovid to be prescribed for high-risk COVID-19 patients.READ MORE